How covid-19 has accelerated the use of AI in healthcare. Our latest in the Wharton Magazine. Builds on Recon Strategy's framework for @PHSInnovation #WMIF and a TiE Boston webinar on the topic. The Wharton School Wharton Healthcare magazine.wharton.upenn.edu/digital/covid-…

Businesses and universities need frequent Covid-19 testing to resume in-person interaction. Online marketplaces for “assurance testing,” as Nikhil Bhojwani and Atul Gawande call it in Harvard Business Review make it simpler and cheaper to test at scale hbr.org/2020/07/a-bett…

3. Responding to lack of testing infrastructure, @CICcambridge member Nikhil Bhojwani of Recon Strategy collaborated with Dr. Atul Gawande on a blueprint for scaling COVID-19 testing in the U.S., coining "assurance testing" as a key step towards reopening. cic.com/blogpost/2021/…

Cell and gene therapies aim to cure rare diseases and oncology AND they also address major chronic conditions including #diabetes. Insights from #WMIF2021 Recon Strategy, Mass General Brigham Innovation worldmedicalinnovation.org/white-paper/

Thank you to our World Medical Innovation Forum Collaborators @Amplify_Bio Boston Scientific CanonUSA @CatalentPharma InterSystems NLVC Amazon One Medical Recon Strategy Siemens Healthineers Thermo Fisher Vertex Pharmaceuticals #WMIF2021

1) Continue to prioritize employees’ wellbeing 2) Be adaptive 3) Step up your comms big time 4) Rethink your biases at work 5) Learn from “Zoom natives” 6) Don’t rush to declare the future Solid advice from Nikhil Bhojwani Recon Strategy & Deborah Lovich Boston Consulting Group hbr.org/2021/08/has-th…

Is this going to be the decade when genomic testing becomes ubiquitous? Investment level is mind boggling and like the heyday of early biotech. Recon Strategy's Sarah Dolman, has a great piece on picking the winners "The Road Ahead for Genomic Testing" recon.blog/road-ahead-for…

Opinion: An effort to develop policies and incentives that support innovation with generics is worth pursuing to leverage the treasure trove of drugs that have been developed over the past decades. buff.ly/3roVxuh

Thoughtful and constructive ideas from Recon Strategy about how to enable repurposing of off-patent molecules. IMHO, legal and regulatory change to enable an ownership option is the most effective course.

Genomic sequencing of all babies is critical as progressive degenerative diseases have a narrow window for therapeutic interventions. Diagnosing after symptoms is too late. #WMIF2022 Robert C. Green Adam Shaywitz Mass General Brigham Innovation

We need to decouple technology platforms from product development in gene and cell therapy so every biotech is not trying to reinvent the wheel Rahul Singhvi from Resilience at #WMIF2022

Thank you to our sponsors Bank of America Novartis US Astellas Pharma US Bayer U.S. 🇺🇸 Recon Strategy Cell&Gene for helping to make #WMIF2022 possible! worldmedicalinnovation.org/sponsors/?cid=…

The amazing "Disruptive Dozen" gene and cell therapies at #WMIF2022 will transform care. #7 restores the "brain of the gut." Truly transformative stuff #WMIF2022 Mass General Brigham Innovation. U.S. FDA good to hear that you're looking for new ways to get these to more patients faster.

Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. By Anna Rose Welch cellandgene.com/doc/arw-s-c-g-…

So where's AI in healthcare going next. One window into this is analysis of clinical trial data which capture some dramatic shifts reconstrategy.com/2022/06/advanc…

Location analysis of Amazon's One Medical (primary care) acquisition by Recon Strategy. About 2/3 of ONEM's commercial clinics are within 1 mile of a Whole Foods store. "clinics are in 13 of Amazon Care's 23 markets of interest for 2022." h/t Nikhil Bhojwani reconstrategy.com/2022/07/whats-…

Pain may have been the graveyard of drug discovery but now we have found the holy grail. Vertex Pharmaceuticals gets the award for the most exciting mixed metaphor at the STAT summit. #pain #biotech

Join us for the last of our Innovate Kidney webinar series hosted by Recon Strategy on June 5th at 4pm ET! You will learn how to effectively commercialize your product in the midst of growing demand and rising market trends. Register today! us06web.zoom.us/webinar/regist…

Biotech analysts studied 229 preclinical asset deals signed between '10–'15 to see which ones reached late stage clinical development & resulted in revenue for licensors h/t Recon Strategy. Assets without a specified target rarely progressed into the clinic which suggests these

In listening to Acquired Podcast on Epic, struck by how well this The Atlantic piece I wrote w Recon Strategy's Tory Wolff & back in 2012(!) -> crossposted @aei: aei.org/articles/is-on… David Rosenthal Ben Gilbert Anticipates many key themes nicely covered by pcast: acquired.fm/episodes/epic-…